Citations - Van Limbergen Erik

BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status... Read more
Published on: 2020-06-17
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
CONCLUSIONS: The MAASTRO applicator was designed to use HDR ^(192)Ir sources to deliver a dose distribution similar to those of CXB devices. The applicator may provide a cost-effective solution for endoluminal boosting with clinical treatment planning system integration.... Read more
Published on: 2020-05-11
Source: Van Limbergen Erik
By: Murillo Bellezzo
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic... Read more
Published on: 2020-05-10
Source: Van Limbergen Erik
By: Relinde I Y Lieverse
  • Other

    Citations

  • Other

    Citations

Translate »